MAS related GPR family member FGenealiases: GPR140 · GPR168 · MRGF · RTA
Q-omics provides the consensus-scored MRGPRF profile across patient tissues and cancer cell-line models. MRGPRF expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MRGPRF is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MRGPRF RNA expression shows 19,550 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where MRGPRF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRF survival associations across molecular data types. MRGPRF RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRF RNA expression–survival associations across cancer types. High MRGPRF expression shows unfavorable associations in KIRP, BLCA and LGG, but favorable associations in HNSC, SARC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for MRGPRF RNA expression.
This table summarizes MRGPRF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MRGPRF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRF shows lower tumor expression in KIRC, BLCA, KIRP, COAD, THCA and UCEC. The KIRC box plot shows higher MRGPRF RNA expression in normal versus tumor tissue (log2 FC = −2.303, t-test p < 0.001).
This table shows molecular features associated with MRGPRF in patient tissues and cancer cell lines. In patient samples, MRGPRF shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRGPRF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
